Immune Network stock trades under OTCBB symbol IMMKF after delisting from CDNX; Update on Alzheimer Disease Trial.Business Editors & Health/Medical Writers VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--Jan. 22, 2002 Immune Network Ltd. (CDNX CDNX See Canadian Venture Exchange (CDNX). :IMM IMM See: International Monetary Market ) (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IMMKF) announced today that January 23 will be its last trading day Last Trading Day The final day that a futures or options contract may trade or be closed out before delivery of the underlying asset must occur. Notes: If the buying and selling parties do not arrange an alternate agreement, the physical commodity must be delivered from on the Canadian Venture Exchange The Canadian Venture Exchange (CDNX) is now a defunct stock exchange having been acquired by the TSX Group in 2001 and renamed the TSX Venture Exchange. History of the Canadian Venture Exchange (CDNX) ("CDNX"). After January 23, the company's common shares will trade only as IMMKF on the OTCBB regardless of whether the shares were purchased through the CDNX or the OTCBB. Shareholders need not take any action with respect to their Immune Network shares. Immune Network stock that was previously traded as "IMM" may now be traded as "IMMKF" in U.S. dollars. Upon delisting from the CDNX, Immune Network intends to engage in appropriate public relations, media relations and investor relations activities that are commensurate with the current stage in the company's growth and its drug development projects. For over a year, Immune Network has been funding a major clinical trial of an existing drug for its use as a treatment for Alzheimer disease. The DAD2000 clinical trial involves 4 countries, 20 centers, and over 30 clinicians. In June 2001, patient enrollment in DAD2000 reached 201 patients whose diagnosis was "mild to moderate" Alzheimer disease. Immune Network is now developing a "compassionate use" program in certain countries for patients who have completed the 52-week clinical trial. Immune Network's drug development pipeline also includes a monoclonal antibody project targeted at treating HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. infections, as well as other earlier stage projects. For historical reasons, Immune Network is also a significant shareholder in a revenue-producing Canadian company, Fitaccess Technologies Inc. (http://www.fitaccess.com), the developer of an internet-based fitness management application already being used by various YMCA facilities in Canada. On behalf of the Board of Directors, Allen Bain, Ph.D., CEO "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward looking statements that are not historical facts and are subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied herein. These risks are described in detail in the company's Securities and Exchange Commission filings. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion